RESEARCH TRIANGLE PARK – Another change in leadership is taking place at drug giant GlaxoSmith Kline.

Jack Bailey, the president of US Pharmaceuticals who oversees GSK’s operations in RTP, is stepping down from the job but will remain as a consultant to GSK through 2020, GSK disclosed Monday.

Replacing him is Maya Martinez-Davis, a pharma industry veteran who currently is Regional President, Latin America Region at EMD Serono, the biopharmaceutical business of Merck KGaA. She will take over the US job in September.

The change is the latest made by Emma Walmsley, who replaced Andrew Witty nearly three years ago. She also has made numerous changes in organization and direction of the company, which maintains R&D operations in RTP and a manufacturing plant in Zebulon.

“Most recently, longtime Chief Financial Officer Simon Dingemans left in May, and next up is chairman Sir Philip Hampton, who will turn the reins over to ex-Novartis and AstraZeneca Chief Financial Officer Jonathan Symonds Aug. 31,” FiercePharma notes.

GSK stops Ebola vaccine development, turns projects over to institute

“GSK continues to evolve its business,” GSK said in a statement explaining the change.

“This includes an expanded pipeline and preparing launches of oncology medicines. Martinez-Davis brings outstanding experience of successfully bringing new specialty care treatments to patients. She is currently Regional President, Latin America Region and was previously SVP, Global Oncology at EMD Serono (Merck KGaA). Prior to this, she spent thirteen years at Pfizer leading various business units around the world including Oncology and Vaccines.”

GSK and Pfizer officially merge healthcare businesses

In a statement, Bailey noted:

“After more than a decade at GSK and nearly three decades in the life sciences industry, I look forward to the chance to explore my next professional chapter. I am enormously proud of every GSK US colleague who has worked so hard to both navigate an exceptionally dynamic operating environment while returning the US Affiliate to double digit revenue growth these past several years. I am confident the company will build upon the talent, culture and performance success of the US Affiliate as it now expands its portfolio into oncology.”

GSK to merge healthcare business with Pfizer, plans to split in two